We are very pleased to have Amyrt Pharma’s support for the 1st Global Congress on EB!
In January 2020 approximately 500 world opinion leaders, academics, practitioners, and patient representatives will meet in London for four days to share state-of-the-art knowledge on epidermolysis bullosa (EB). As this is the first time that such a comprehensive gathering will come together, it presents an exciting and unique opportunity for companies to get involved and sponsor the event. Together we can do more! Read below to find out more about our valued platinum sponsor:
1. Tell us a bit about your company.
Amryt Pharma is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. One of our most exciting research programmes is focused on developing transformative treatments for people with EB.
What do we mean by transformative? Well, we are committed to transforming what it means to live with EB for the better. We are pursuing a number of different approaches in our clinical development programme with the potential to make life better for people with EB, which range from improving wound healing to addressing the underlying causes of EB itself in the hope of developing a cure.
2. What is your mission or goal as a company/organisation?
We believe that a breakthrough for people living with EB is possible, and at Amryt Pharma we are focused on this important goal and are motivated through interaction and collaboration with the EB community to do all we can to make a cure a reality.
3. How is your company/organisation involved with EB?
Our primary role is researching potential new treatments for EB. However, while our focus is on our research, this doesn’t mean we spend all our time in a lab!
We are always looking at ways that we can support the EB community. In recent years, we have actively partnered with many of the Debras and other organisations that work with people living with EB to raise awareness of the condition, support fundraising efforts and initiate research to help generate data which can be useful for both researchers and clinicians.
4. What are you looking forward to about EB 2020? Why did you decide to get involved?
We are delighted that Amryt Pharma are platinum sponsors of the first EB World Congress. Collaboration is central to the way we work and we believe that through working together with the EB community we can make real progress for patients with EB. We are looking forward to sharing our research, meeting potential new partners and learning from experts. Above all, we are looking forward to meeting many new members of the EB global community and to consider how we can optimise our future efforts to provide hope to those with the greatest need.
5. What does the future of EB look like to your company?
Amryt is running two key research programmes in EB with the hope of delivering transformative treatments that can improve symptoms and potentially offer a cure. This includes running the largest ever global trial in EB with Oleogel-S10, the EASE trial, at 55 sites in 27 countries, and we look forward to these results in 2020 with great anticipation. We also look forward to initiating the clinical development of our non-viral gene therapy platform. We believe in a future where people living with EB can enjoy a better quality of life than today, and we hope to contribute to making that a reality.
For additional information about Amyrt, please visit: https://www.amrytpharma.com
For information about sponsorship, please visit: https://ebworldcongress.org/sponsors/sponsorship/